Beizray is a drug owned by Zhuhai Beihai Biotech Co Ltd. It is protected by 3 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 16, 2036. Details of Beizray's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12090134 | Neutral pH compositions of docetaxel and human serum albumin |
May, 2036
(10 years from now) | Active |
| US11419842 | Neutral pH compositions of Docetaxel and human serum albumin |
May, 2036
(10 years from now) | Active |
| US12090135 | Neutral pH compositions of docetaxel and human serum albumin |
May, 2036
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Beizray's patents.
Latest Legal Activities on Beizray's Patents
Given below is the list of recent legal activities going on the following patents of Beizray.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 17 Sep, 2024 | US12090135 |
| Recordation of Patent eGrant | 17 Sep, 2024 | US12090134 |
| Email Notification | 17 Sep, 2024 | US12090135 |
| Mail Patent eGrant Notification | 17 Sep, 2024 | US12090135 |
| Patent eGrant Notification | 17 Sep, 2024 | US12090134 |
| Mail Patent eGrant Notification | 17 Sep, 2024 | US12090134 |
| Email Notification | 17 Sep, 2024 | US12090134 |
| Patent Issue Date Used in PTA Calculation | 17 Sep, 2024 | US12090134 |
| Recordation of Patent Grant Mailed | 17 Sep, 2024 | US12090134 |
| Patent Issue Date Used in PTA Calculation | 17 Sep, 2024 | US12090135 |
US patents provide insights into the exclusivity only within the United States, but
Beizray is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Beizray's family patents as well as insights into
ongoing legal events
on those patents.
Beizray's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Beizray's generic launch date based on the expiry of its last outstanding patent is estimated to be May 16, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Beizray Generic API suppliers:
Docetaxel is the generic name for the brand Beizray. 16 different companies have already filed for the generic of Beizray, with Mylan Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Beizray's generic
Alternative Brands for Beizray
There are several other brand drugs using the same active ingredient (Docetaxel) as Beizray. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Docetaxel, Beizray's active ingredient. Check the complete list of approved generic manufacturers for Beizray
About Beizray
Beizray is a drug owned by Zhuhai Beihai Biotech Co Ltd. Beizray uses Docetaxel as an active ingredient. Beizray was launched by Zhuhai in 2024.
Approval Date:
Beizray was approved by FDA for market use on 23 October, 2024.
Active Ingredient:
Beizray uses Docetaxel as the active ingredient. Check out other Drugs and Companies using Docetaxel ingredient
Dosage:
Beizray is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 80MG/4ML (20MG/ML) | SOLUTION | Prescription | INTRAVENOUS |